Heike Daldrup-Link

Publication Details

  • Phase II clinical evaluation of Gd-EOB-DTPA: Dose, safety aspects, and pulse sequence RADIOLOGY Reimer, P., Rummeny, E. J., Shamsi, K., Balzer, T., Daldrup, H. E., Tombach, B., Hesse, T., Berns, T., Peters, P. E. 1996; 199 (1): 177-183


    To investigate the efficacy of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) in the detection of focal liver lesions with respect to dose, side effects, and pulse sequence.A randomized double-blinded trial was performed in 33 patients with focal solid liver lesions. A bolus of Gd-EOB-DTPA, a liver-specific contrast agent, was intravenously administered at three different doses (12.5, 25, and 50 mumol per kilogram of body weight). Magnetic resonance imaging with different T1-weighted techniques was performed 20 and 45 minutes after administration of Gd-EOB-DTPA. Changes in liver signal intensity, lesion-liver contrast-to-noise ration (C/N), detectable liver lesions, side effects, and adverse events were evaluated.Gd-EOB-DTPA significantly (P < .05) increased liver signal intensity and lesion-liver C/N within the dose range tested. Lesion detection was improved 20 and 45 minutes after administration of Gd-EOB-DTPA. A dose of 12.5 mumol was sufficient for the detection of focal liver lesions, and the breath-hold, T1-weighted, fast low-angle shot pulse sequence was the most useful. No significant changes in vital signs, clinical laboratory test results, and urinalysis were observed.Gd-EOB-DTPA is an efficient, diagnostically useful, and safe contrast agent.

    View details for Web of Science ID A1996UB58400030

    View details for PubMedID 8633143

Stanford Medicine Resources:

Footer Links: